Stock Commentary: Iovance Biotherapeutics (IOVA)—ARK Invest email
It's Friday, May 21, 2021
Hello James,
We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week.
In addition, given recent market volatility, we invite you to read our latest market commentary that provides a review of the dynamics at play. Please click here.
We hope you find these commentaries useful.
Iovance Biotherapeutics (IOVA)
39%
Iovance Biotherapeutics (IOVA), a leader in tumor-infiltrating lymphocyte (TIL) immunotherapy, closed down 39% on Wednesday. On Tuesday, Iovance announced that it was delaying its Biologics License Application (BLA) from the second half of 2021 to the first half of 2022 because of FDA feedback on its potency assays.
On Wednesday, the company disclosed that Maria Fardis, CEO of the company for the last five years, was leaving “to pursue other opportunities,” and that General Counsel Frederick Vogt would be stepping in as interim CEO.
We believe that Iovance’s TILs will continue to be the most compelling therapy for solid tumors in the market and that Iovance has the most robust TIL data set. Furthermore, in our view, Iovance is trail-blazing the FDA regulatory process and likely will get FDA approval for its TIL therapy to treat melanoma, a very difficult-to-treat disease with high unmet need.
ARK's statements are not an endorsement of any company or a recommendation to buy, sell or hold any security. For a list of all purchases and sales made by ARK for client accounts during the past year that could be considered by the SEC as recommendations, click here. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this list. For full disclosures, click here.
Copyright © 2021 ARK Investment Management LLC, All rights reserved.
3 East 28th Street, Floor 7
New York, NY 10016 United States
You received this email because you are subscribed to ARK Advisor Services (Updates and Reports) from ARK Investment Management LLC.
Unsubscribe from ARK emails or choose the types of emails you want to receive. Unsubscribe from all.
This Newsletter is for informational purposes only and does not constitute, either explicitly or implicitly, any provision of services or products by ARK Investment Management LLC (“ARK”). Investors should determine for themselves whether a particular service or product is suitable for their investment needs or should seek such professional advice for their particular situation. All content is original and has been researched and produced by ARK unless otherwise stated therein. No part of the content may be reproduced in any form, or referred to in any other publication, without the express written permission of ARK. All statements made regarding companies, securities or other financial information contained in the content or articles relating to ARK are strictly beliefs and points of view held by ARK and are not endorsements of any company or security or recommendations to buy or sell any security. By visiting and/or otherwise using the ARK website in any way, you indicate that you understand and accept the terms of use as set forth on the website and agree to be bound by them. If you do not agree to the terms of use of the website, please do no access the website or any pages thereof. Any descriptions of, references to, or links to other products, publications or services does not constitute an endorsement, authorization, sponsorship by or affiliation with ARK with respect to any linked site or its sponsor, unless expressly stated by ARK. Any such information, products or sites have not necessarily been reviewed by ARK and are provided or maintained by third parties over whom ARK exercises no control. ARK expressly disclaims any responsibility for the content, the accuracy of the information, and/or quality of products or services provided by or advertised on these third-party sites.